Epizyme, Inc. (NASDAQ:EPZM) insider Jeffery Kutok sold 2,029 shares of the business’s stock in a transaction that occurred on Monday, April 5th. The stock was sold at an average price of $8.80, for a total value of $17,855.20. Following the transaction, the insider now directly owns 54,028 shares in the company, valued at $475,446.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of EPZM opened at $8.44 on Thursday. The business’s 50 day moving average is $9.21 and its two-hundred day moving average is $11.31. Epizyme, Inc. has a 52-week low of $7.44 and a 52-week high of $22.00. The firm has a market cap of $859.07 million, a price-to-earnings ratio of -3.78 and a beta of 1.76. The company has a quick ratio of 8.71, a current ratio of 8.95 and a debt-to-equity ratio of 0.33.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, February 22nd. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.06). Epizyme had a negative net margin of 1,899.35% and a negative return on equity of 83.45%. The firm had revenue of $8.38 billion during the quarter, compared to the consensus estimate of $6.55 million. The company’s revenue for the quarter was up 95.0% on a year-over-year basis. On average, equities analysts expect that Epizyme, Inc. will post -2.23 earnings per share for the current fiscal year.
Several research firms recently commented on EPZM. Citigroup reduced their price target on Epizyme from $35.00 to $27.00 in a research report on Wednesday, February 24th. Credit Suisse Group began coverage on Epizyme in a research report on Tuesday, March 30th. They set an “outperform” rating and a $13.00 price target on the stock. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, February 9th. Wedbush reissued an “outperform” rating on shares of Epizyme in a research report on Tuesday, February 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $14.00 target price on shares of Epizyme in a research report on Wednesday, March 3rd. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $16.38.
Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.
Featured Story: What is a conference call?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.